Skip to main content

Revatio Disease Interactions

There are 10 disease interactions with Revatio (sildenafil).

Major

PDE5 inhibitors (applies to Revatio) cardiovascular disease

Major Potential Hazard, High plausibility. Applicable conditions: Hypotension, History - Cerebrovascular Disease, Cerebral Vascular Disorder, History - Myocardial Infarction

The use of phosphodiesterase-5 (PDE5) inhibitors is not recommended in patients with preexisting cardiovascular disease for whom sexual activity is inadvisable due to the potential cardiac risk. Physicians should also consider the vasodilatory effect of these drugs and whether they may adversely affect patients with underlying cardio- and/or cerebrovascular conditions, in particular those who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; those with resting hypotension (BP < 90/50) or hypertension (BP > 170/110); and those with unstable angina associated with cardiac failure or coronary artery disease. There are no controlled clinical data on the safety or efficacy in such patients. Other adverse cardiovascular effects reported include angina pectoris, myocardial infarction, AV block, ventricular arrhythmia, tachycardia, palpitation, hypotension, postural hypotension, syncope, cerebral thrombosis, cerebrovascular hemorrhage, transient ischemic attack, cardiac arrest, heart failure, and hypertension. Many of these events occurred in patients with cardiovascular risk factors and during or shortly after sexual activity.

References

  1. (2001) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals
  2. Feenstra J, vanDriePierik RJHM, Lacle CF, Stricker BHC (1998) "Acute myocardial infarction associated with sildenafil." Lancet, 352, p. 957-8
  3. Goldenberg MM (1998) "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther, 20, p. 1033-48
  4. Zusman RM (1999) "Cardiovascular data on sildenafil citrate - Introduction." Am J Cardiol, 83, c1-2
  5. Conti CR, Pepine CJ, Sweeney M (1999) "Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease." Am J Cardiol, 83, c29-34
  6. Zusman RM, Morales A, Glasser DB, Osterloh IH (1999) "Overall cardiovascular profile of sildenafil citrate." Am J Cardiol, 83, c35-44
  7. Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH (1999) "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology, 53, p. 1011-8
  8. Kloner RA, Zusman RM (1999) "Cardiovascular effects of sildenafil citrate and recommendations for its use." Am J Cardiol, 84, n11-7
  9. Awan GM, Calderon E, Dawood G, Alpert MA (2000) "Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy." Am J Med Sci, 320, p. 69-71
  10. Kloner RA (2000) "Cardiovascular risk and sildenafil." Am J Cardiol, 86, f57-61
  11. Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED (2000) "Side-effect profile of sildenafil citrate (Viagra) in clinical practice." Urology, 56, p. 474-6
  12. McMahon CG, Smali R, Johnson H (2000) "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol, 164, p. 1192-6
  13. Malozowski S, Sahlroot JT (2000) "Hemodynamic effects of sildenafil." N Engl J Med, 343, p. 967-8
  14. Dunn N (2001) "Cardiovascular events in users of sildenafil - Paper does not provide any reassurance." Br Med J, 323, p. 50-1
  15. (2003) "Product Information. Levitra (vardenafil)." Bayer
  16. (2003) "Product Information. Cialis (tadalafil)." Lilly, Eli and Company
  17. Curran M, Keating G (2003) "Tadalafil." Drugs, 63, 2203-12; discussion 2213-4
  18. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  19. (2012) "Product Information. Stendra (avanafil)." Vivus Inc
  20. (2023) "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group, SUPPL-25
  21. (2017) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals Group
  22. (2023) "Product Information. Liqrev (sildenafil)." Carolina Medical Products Company
View all 22 references
Moderate

PDE 5 inhibitors (applies to Revatio) priapism

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Myeloproliferative Disorder, Sickle Cell Anemia, Peyronie's Disease, Cavernosal/Penile Tissue Abnormalities

Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors. Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly. These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie's disease). If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.

References

  1. Kassim AA, Fabry ME, Nagel RL (2000) "Acute priapism associated with the use of sildenafil in a patient with sickle cell trait." Blood, 95, p. 1878-9
  2. (2003) "Product Information. Levitra (vardenafil)." Bayer
  3. (2003) "Product Information. Cialis (tadalafil)." Lilly, Eli and Company
  4. (2009) "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation
  5. (2012) "Product Information. Stendra (avanafil)." Vivus Inc
  6. (2014) "Product Information. Staxyn (vardenafil)." Merck & Co., Inc
  7. (2023) "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group, SUPPL-25
  8. (2017) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals Group
  9. (2023) "Product Information. Liqrev (sildenafil)." Carolina Medical Products Company
View all 9 references
Moderate

PDE5 inhibitors (applies to Revatio) alcoholism

Moderate Potential Hazard, Moderate plausibility.

Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors. Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.

References

  1. (2003) "Product Information. Levitra (vardenafil)." Bayer
  2. (2003) "Product Information. Cialis (tadalafil)." Lilly, Eli and Company
  3. (2009) "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation
  4. (2012) "Product Information. Stendra (avanafil)." Vivus Inc
  5. (2014) "Product Information. Staxyn (vardenafil)." Merck & Co., Inc
  6. (2023) "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group, SUPPL-25
  7. (2017) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals Group
  8. (2023) "Product Information. Liqrev (sildenafil)." Carolina Medical Products Company
View all 8 references
Moderate

PDE5 inhibitors (applies to Revatio) hearing loss

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Tinnitus

Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness. Patients with hearing problems should stop taking these agents and seek prompt medical care.

References

  1. (2003) "Product Information. Levitra (vardenafil)." Bayer
  2. (2003) "Product Information. Cialis (tadalafil)." Lilly, Eli and Company
  3. (2009) "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation
  4. (2012) "Product Information. Stendra (avanafil)." Vivus Inc
  5. (2014) "Product Information. Staxyn (vardenafil)." Merck & Co., Inc
  6. (2023) "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group, SUPPL-25
  7. (2017) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals Group
  8. (2023) "Product Information. Liqrev (sildenafil)." Carolina Medical Products Company
View all 8 references
Moderate

PDE5 inhibitors (applies to Revatio) liver disease

Moderate Potential Hazard, High plausibility.

Phosphodiesterase 5 (PDE-5) inhibitors are cleared predominantly by hepatic metabolism. The pharmacokinetic disposition of these agents has not been assessed in patients with severe hepatic impairment. No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with these agents should not be administered to patients with severe hepatic impairment. In patients with mild hepatic impairment a lower dose of these agents should be used as initial therapy.

References

  1. (2003) "Product Information. Cialis (tadalafil)." Lilly, Eli and Company
  2. (2009) "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation
  3. (2012) "Product Information. Stendra (avanafil)." Vivus Inc
  4. (2023) "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group, SUPPL-25
  5. (2017) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals Group
  6. (2023) "Product Information. Liqrev (sildenafil)." Carolina Medical Products Company
View all 6 references
Moderate

PDE5 inhibitors (applies to Revatio) seizure disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Seizures

The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures. Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.

References

  1. (2001) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals
  2. (2003) "Product Information. Levitra (vardenafil)." Bayer
  3. (2003) "Product Information. Cialis (tadalafil)." Lilly, Eli and Company
  4. (2005) "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group
  5. (2009) "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation
  6. (2012) "Product Information. Stendra (avanafil)." Vivus Inc
  7. (2014) "Product Information. Staxyn (vardenafil)." Merck & Co., Inc
View all 7 references
Moderate

Sildenafil (applies to Revatio) sickle cell disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Sickle Cell Anemia

The safety and efficacy of sildenafil for the treatment of pulmonary hypertension secondary to sickle cell disease has not been established; vaso-occlusive crises requiring hospitalization were more commonly reported in this population.

References

  1. (2023) "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group, SUPPL-25
  2. (2017) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals Group
  3. (2023) "Product Information. Liqrev (sildenafil)." Carolina Medical Products Company
Moderate

Sildenafil (applies to Revatio) bleeding disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bleeding Associated with Coagulation Defect, Peptic Ulcer

The safety of sildenafil in patients with bleeding disorders or active peptic ulceration is unknown. In clinical studies, the incidence of bleeding (i.e., epistaxis) was increased in patients with pulmonary arterial hypertension secondary to connective tissue disease and in patients on concomitant therapy with an oral vitamin K antagonist. There have been postmarketing reports of bleeding events in patients treated with sildenafil for erectile dysfunction.

References

  1. (2023) "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group, SUPPL-25
  2. (2017) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals Group
  3. (2023) "Product Information. Liqrev (sildenafil)." Carolina Medical Products Company
Moderate

Sildenafil (applies to Revatio) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Exposure to sildenafil is increased in patients with renal dysfunction. Lower starting doses of sildenafil for the treatment of erectile dysfunction (ED) are recommended in patients with severe renal impairment (CrCl less than 30 mL/min). When sildenafil is used for the treatment of pulmonary arterial hypertension, no dose adjustment is recommended for any degree of renal impairment.

References

  1. (2023) "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group, SUPPL-25
  2. (2017) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals Group
  3. (2023) "Product Information. Liqrev (sildenafil)." Carolina Medical Products Company
Moderate

Sildenafil (applies to Revatio) visual disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Visual Defect/Disturbance, Retinitis Pigmentosa, Optic Nerve Disorder

Sildenafil for the treatment of erectile dysfunction (ED) should be used with caution and only if the benefit outweighs the risk in patients with a history of non-arteritic anterior ischemic optic neuropathy (NAION) or with retinitis pigmentosa. Use of sildenafil for the treatment of pulmonary arterial hypertension is not recommended in patients with retinitis pigmentosa. Advise patients to seek immediate medical attention in the event of a sudden loss of vision in one or both eyes while taking sildenafil; patients taking sildenafil for ED should immediately stop treatment. Most patients who developed NAION during therapy with sildenafil had underlying anatomic or vascular risk factors, including low cup to disc ratio ("crowded disc").

References

  1. (2023) "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group, SUPPL-25
  2. (2017) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals Group
  3. (2023) "Product Information. Liqrev (sildenafil)." Carolina Medical Products Company

Revatio drug interactions

There are 333 drug interactions with Revatio (sildenafil).

Revatio alcohol/food interactions

There are 2 alcohol/food interactions with Revatio (sildenafil).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.